USFDA flags eight issues with Ipca Labs: The US Food and Drug Administration (USFDA) has found eight issues with Ipca Labs in its inspection of the company's facilities in Indore and Pithampur. After finding objections with the company's facilities at different places, the FDA has also issued Form 483 to the company. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

USFDA conducted investigation between June 15 and 23 and found objections with the company's facilities in Ratlam, Indore, and Pithampur.

It tested at the company's formulations manufacturing facility at Pithampur and issued Form 483 after finding 8 objections. 

The American regulatory authority also found 11 objections at the API plant of Ratlam., which was inspected from June 5 to June 13. 
 

Import Alert 

After the FDA investigation, Ipca Labs' facilities in Ratlam and Pithampur are under an import alert.

The US regulatory body said that the company needed to resolve the objections the FDA has raised in Form 483.

It further said that the Ratlam and Pithampur facilities require clean chit for recovery in the US generics business.

Among the prominent objections, that the FDA found were: the company's failure in the quality unit associated with the API batch; its lack of consistency in processing condition, which raises critical quality questions regarding the quality; lack of efficiency in maintaining record properly.